If either DCs and/ or xALT do not meet release criteria or targeted dose then the patient may remain on study and receive the qualified product but will be replaced for the purposes of safety assessment. For the purpose of this study, progression will be defined as a new lesion confirmed by biopsy or resection, positive cerebrospinal fluid (CSF) cytology, or a new metastatic lesion (if previously negative). 15.2.2 LEUKAPHERESIS FOR PE RIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS ) • Intravenous Access : PBMCs will be obtained by placing two large gauge catheters into the antecubital veins bilaterally or by using a dialysis -type central venous catheter that will allow for large volume apheresis . • PBMC Mobilization : Patients will not receive mobilization p rior to leukapheresis. • Apheresis Machine: The choice of apheresis machine is at the discretion of the institution . • Blood Priming: Blood priming of the apheresis machine is at the discretion of the institution . • Apheresis Procedure: The apheresis machine set tings, procedure duration, and volume of whole blood processed shall be in accordance with SOP -UFBTIP- 131. • PBMC Collection Goal: The collection goal for TTRNA -xALT and TTRNA -pulsed Dendritic Cell vaccine is a minimum of 5x109 mononuclear cells . • Product Testing : An aliquot of cryopreserved TTRNA -xALT and TTRNA -pulsed Dendritic Cells will be thawed and prepared for QC testing and must meet batch release criteria. 15.2.3 PBSC MOBILIZATION AND LEUKAPHERESIS • Leukapheresis products previously collected and cryopreserved may be used for this protocol as long as the cells meet all standard release criteria and transfer agreements for use of the product s, if applicable, are executed . • Intravenous Access : PBSC s will be collected using a dialysis -type catheter that will allow for large volume apheresis . • PBSC Mobilization : Patients will begin G -CSF (5 mcg/kg/day ) 24-36 hours after completion of chemotherapy. When the WBC count starts recovering (WBC > 1,000 post nadir or in accordance with institutional standards), increase the G -CSF dose to 10mcg/kg/day. PBSC collection will begin when the circulating CD34 • cell count is > 10 cells/ μL or in accordance with institutional standard s. G-CSF will continue until PBSC collection is complete. It is recommended that G -CSF be administered at night (approximately 2200) on the days(s) prior to scheduled leukapheresis. If the post-G-CSF WBC is > 60,000, decrease the G-CSF dose to 5mcg/kg. • Apheresis Machine: The choice of apheresis machine is at the discretion of the institution .